What question did this study set out to answer?

To evaluate the pharmacokinetic profile of the low molecular weight heparin Fraxiparine across various degrees of chronic renal failure.

December 11, 2008The Nephron journals/Nephron journals

Pharmacokinetics of a Low Molecular Weight Heparin (Fraxiparine®) in Various Stages of Chronic Renal Failure

View Full Paper

Ask AI

Bookmark

Why the study?

Does chronic renal insufficiency alter the pharmacokinetics of low molecular weight heparin compared to healthy volunteers?

Population

19 patients with chronic renal insufficiency of various severity and 12 healthy volunteers. Total n=31.

Comparison

Low molecular weight heparin single bolus… vs Healthy volunteers (n=12)

Design

Cohort

Authors

CGCatherine GoudableHôpital de La Grave SSSylvie SaivinCentre Hospitalier Universitaire de Toulouse GHGeorges HouinCentre National de la Recherche Scientifique

Discussion

Member takes

Implication

LMWH half-life prolongation in renal insufficiency leaves open optimal dosing and monitoring strategies pending prospective trials.

Key Points

To evaluate the pharmacokinetic profile of the low molecular weight heparin Fraxiparine across various degrees of chronic renal failure.
Administered a single intravenous bolus injection of 100 antifactor Xa IC U/kg of Fraxiparine to 19 patients across three severity groups: hemodialysis (group A, n=7), creatinine clearance 10–20 ml/min (group B, n=7), and creatinine clearance 30–50 ml/min (group C, n=5).
Compared pharmacokinetic parameters among the three patient cohorts and against a historical control group of 12 healthy volunteers.
Pharmacokinetic parameters did not differ significantly between the three renal failure groups and showed no linear correlation with creatinine clearance.
The elimination half-life of antifactor Xa activity was significantly prolonged in all three renal failure groups compared with healthy volunteers.

Structured PICO

Does chronic renal insufficiency alter the pharmacokinetics of low molecular weight heparin compared to healthy volunteers?

Population

19 patients with chronic renal insufficiency of various severity (hemodialyzed n=7, creatinine clearance 10-20 ml/min n=7, creatinine clearance 30-50 ml/min n=5) and 12 healthy volunteers. Total n=31.

Intervention

Low molecular weight heparin (Fraxiparine) single bolus intravenous injection of 100 antifactor Xa IC U.kg-1

Comparator

Healthy volunteers (n=12)

Outcome

Pharmacokinetic parameters (half-life of disappearance of antifactor Xa activity)surrogate

Low molecular weight heparin exhibits a prolonged half-life in patients with chronic renal insufficiency, necessitating monitoring of antifactor Xa activity to prevent accumulation.

Cite This Study

Goudable et al. (2008) studied this question.

synapsesocial.com/papers/6a6fecfbfebe604dd708bf3a https://doi.org/10.1159/000186641

View Full Paper

Ask AI

Bookmark